|
| |
Osiris TherapeuticsLeading the way to a better tomorrow
Osiris Therapeutics, Inc. is a company founded to commercialize stem cell products from adult bone marrow. These stem cells have demonstrated the ability to repair different types of tissues.
The next revolution in medical care
Osiris Therapeutics is commercializing products from a readily available and non-controversial source – adult bone marrow. These stem cells have demonstrated the ability to repair different types of tissue and offer a very real opportunity to develop revolutionary new treatments for certain disease processes including autoimmune disorders, heart attacks and arthritis.
Osiris’ technology is based on the pioneering work of Dr. Arnold Caplan and his colleagues at Case Western Reserve University. They showed that Mesenchymal Stem Cells (MSCs) can engraft and selectively differentiate, based on the tissue environment, to such lineages as muscle, bone, cartilage, marrow stroma, tendon and fat. Due to their cellular origin and phenotype, these cells do not provoke an immune response, allowing for the development of products derived from unrelated human donors.
| Contact Details: |
| 2001 Aliceanna Street |
| Baltimore |
| MD |
| 21231 |
| United States of America |
| Tel: | 410 522 5005 |
| Fax: | 410 522 6999 |
| Email: | osiris@Osiris.com |
| WWW: | www.osiris.com/
|
|
Loading...
|
Recent Publications by Osiris Therapeutics: |  |
Treatment of inflammatory diseases with mesenchymal stem cells.
Human mesenchymal stem cells (hMSCs) are rare progenitor cells present in... | 18th June, 2009
| Osiris Therapeutics, Inc., 7015 Albert Einstein Drive, Columbia, MD 21046,
| Inflamm Allergy Drug Targets. 2009 Jun;8(2):110-23.
|
Purification of sequence-specific DNA-binding proteins by affinity chromatography.
The affinity chromatography procedure described in this unit uses DNA... | 17th June, 2008
| Osiris Therapeutics, Baltimore, Maryland, USA.
| Curr Protoc Protein Sci. 2001 May;Chapter 9:Unit 9.6.
DOI Direct Link |
Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons.
Mesenchymal stem cells (MSCs) express low immunogenicity and demonstrate... | 19th June, 2007
| Osiris Therapeutics, Inc., Baltimore, MD, USA.
| Cell Transplant. 2006;15(8-9):711-21.
|
Donor hematopoietic cells from transgenic mice that express GFP are immunogenic in immunocompetent recipients.
OBJECTIVE: To study the immunogenicity of hematopoietic cells marked with... | 31st December, 2005
| Osiris Therapeutics Inc., 2001 Aliceanna Street, Baltimore, MD 21231, USA.
| Hematology. 2005 Aug;10(4):289-95.
DOI Direct Link |
T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression.
Human mesenchymal stem cells (MSCs) were evaluated for their ability to... | 28th October, 2005
| Osiris Therapeutics, Inc., 2001 Aliceanna Street, Baltimore, MD 21231,
| J Biomed Sci. 2005;12(1):47-57.
DOI Direct Link |
→View more Osiris Therapeutics research publications. |
Press Releases on Osiris Therapeutics:
|
 |
| Reportlinker Adds Global Stem Cell and Advanced Technologies Market |
10th November, 2009 |
Reportlinker |
-- Stem Cell Applications (regenerative medicine - neurological disorders,
orthopedics, cancer, hematological disorders, myocardial infarction and
cardiovascular diseases,
|
| MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 |
3rd November, 2009 |
|
WILMINGTON, Delaware, November 3 /PRNewswire/ -- The new market research report, 'Global Stem Cell and Advanced
Technologies Market' (2009 - 2014)', published by MarketsandMarkets
(http
|
| Reportlinker Adds Stem Cell Therapeutics Markets Report |
24th September, 2009 |
Reportlinker |
-- Cardiovascular disease
-- Lung disease
-- Arthritis
-- Incontinence
-- Osteoporosis
-- Diabetes
-- Cancer
-- Orthopedics
|
| AssureRx Adds New CEO |
9th June, 2009 |
AssureRx |
Experienced Executive to Lead Personalized Medicine Company in Next Phase of Growth
CINCINNATI, June 9 /PRNewswire/ -- AssureRx, a personalized medicine company, announced today that James S. Burns
|
| Former Executive at Genzyme Corp. and Osiris Therapeutics, Inc. to Head Business Advisory Board at Rx for Africa, Inc. |
13th April, 2009 |
|
NEW YORK, April 13 /PRNewswire/ -- A top biotech executive, William Pursley, has agreed to become Chairman
of Rx for Africa, Inc.'s (Pink Sheets: RXAF) newly created Business Advisory
Board. For
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 14 individuals from Osiris Therapeutics using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 603 times since April 2007, the link to the organisation's website has been followed 90 times Recent Search Terms used to find this page: osiris pharmaceuticals Nov,2009 | immunogenicity progenitor cell marrow osteocel | Bill Pursley baltimore md | Bill Pursley baltimore md | OSIRIS TECHNOLOGY COLUMBIA MD | The next revolution in medical care | osiris therapeutics | osyris mesenchymal 2009 | Osiris for allergy | mesenchymal stem cell patent osiris | . Search for more companies in Baltimore Search for more companies in MD This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Osiris Therapeutics |
